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ABSTRACT 
Background: Oral Submucous Fibrosis is a potentially malignant disorder well known for its chronic and resistant nature. The conservative drug 
treatment that is currently available for this disorder is clearly inadequate. The aim of the study was to evaluate the efficacy of oral lycopene 
therapy when used in combination with conventional intralesional steroid therapy in the management of oral submucous fibrosis.Methods: Forty 
five patients with oral submucous fibrosis (grade III and IV) were included under the study and were randomly divided into 3 groups consisting of 
15 cases each: Group A (oral lycopene 16 mg/day with biweekly intralesional steroids and hyaluronidase), Group B (oral antioxidant capsules with 
biweekly intralesional steroids and hyaluronidase) and Group C (biweekly intralesional steroids and hyaluronidase alone). Mouth opening and 
burning sensation were recorded from baseline to 6 weeks. Cases were followed up to 3 and 6 months.Results: There was significant increase in 
mouth opening among all the 3 groups. The results were statistically significant between Group A and C and Group B and C.Conclusion: Lycopene in 
combination with intralesional steroids and Hyaluronidase, is highly efficacious in improving the mouth opening and reducing other symptoms in 
patients with Oral Submucous Fibrosis. No side effects were reported with its usage.   
Keywords: Submucous, anticarcinogenic, cyclooxygenase and lipoxygenase.
INTRODUCTION 
Oral submucous fibrosis (OSF) is a potentially malignant disease that 
is insidious and chronic in nature affecting the entire oral cavity, 
sometimes extending to the pharynx. It has drawn considerable 
attention in recent past due to its high malignant potential and 
chronic debilitating and resistant nature. It is seen predominantly in 
people of Asian descent especially among Indian population [1].  
A variety of etiologic factors including capsaicin, betel nut alkaloids, 
hypersensitivity, autoimmunity, genetic predisposition and chronic 
iron and vitamin B-complex deficiency have been suggested by 
various authors, the most common of which is chewing areca nut. 
Excessive use of areca nut may cause fibrosis due to increased 
synthesis of collagen and induce the production of free radicals and 
reactive oxygen species, which are responsible for high rate of 
oxidation/peroxidation of polyunsaturated fatty acids which affect 
essential constituents of cell membrane and might be involved in 
tumorigenesis [2]. Arecanut chewing is deep rooted in Indian culture 
and has been used as a mouth freshening agent that has various 
symbolic roles throughout Indian history [3]. The most alarming fact 
is that this habit is becoming increasingly popular among 
adolescents. 
The ingredients of arecanut induce excessive reactive oxygen 
species which damages the cell structures, including lipids and 
membranes, proteins and nucleic acids. Moreover vitamin 
deficiency, iron deficiency anaemia, and malnutrition can derange 
the repair of the inflamed oral mucosa, leading to defective healing 
and the resulting atrophic oral mucosa is more susceptible to the 
effects of areca nut. Here comes the role of Antioxidant vitamins that 
stabilize and deactivate the free radicals before they attack cells 2.  
One such type of antioxidant is Lycopene. Lycopene is a 
phytochemical, synthesized by plants (tomatoes) and 
microorganisms but not by animals. It is a powerful antioxidant and 
has a singlet-oxygen-quenching ability twice as high as that of beta-
carotene and ten times higher than that of alpha-tocopherol 2. It is a 
potent anticarcinogenic and has demonstrated profound benefits in 
precancerous lesions like leukoplakia [4]. It has also been suggested 
that no single drug has provided complete relief of symptoms of OSF 
2. So we decided to adopt a combination of drugs to treat OSF. The  
 
aim of the study was to evaluate the efficacy of oral lycopene therapy 
when used in combination with conventional intralesional steroid 
therapy in the management of OSF. 
MATERIALS AND METHODS 
Totally 45 patients with signs and symptoms of OSF were recruited 
for the study from the Department of Oral Medicine and Radiology, 
Tamilnadu Government Dental College and Hospital, Chennai, India. 
The Institute’s Ethical Committee approval was obtained. The 
patients were included under the study only after satisfying the 
following criteria: 
 History of the habit of chewing arecanut or any of its 
commercial products. 
 Burning sensation on eating spicy food. 
 Restricted mouth opening with or without palpable vertical 
fibrous bands on the buccal mucosa with stiffness and 
blanching and without tongue involvement - Grade III and IV 
(Chandra et al [5]) 
Patients with histologically proven OSF turning into malignancy 
were excluded from the study. Informed consent was obtained from 
all the patients. They were then explained about the disease 
condition and its premalignant potential. The patients were then 
counselled to stop the habit of using arecanut in all its forms. 
Complete oral prophylaxis was done to improve the oral hygiene as 
well as to motivate the patient to stop the habit.  
The patients were then randomly divided into three groups (A, B 
and C) consisting of 15 cases each. Group A patients were given oral 
Lycopene capsules 16 mg (Lycostar®, Mankind Pharma Ltd., New 
Delhi, India), one capsule/day along with bi-weekly intralesional 
injections of Dexamethasone 1.5 ml & Hyaluronidase 1500 IU mixed 
with lignocaine. Lycostar contains Lycopene 5000 μg along with 
various micronutrients. Group B patients were given oral 
antioxidant capsules (Multivitamin A-Z soft capsules, PrimePharm, 
Shangai, China), one capsule/day along with bi-weekly intralesional 
injections of Dexamethasone 1.5 ml & Hyaluronidase 1500 IU mixed 
with lignocaine. Group C patients were given bi-weekly intralesional 
injections of Dexamethasone 1.5 ml & Hyaluronidase 1500 IU with 
lignocaine alone without any other oral supplements. 
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Patients were evaluated every week during the treatment period of 
6 weeks. The following parameters were recorded during each 
week:   
Burning sensation 
It was recorded at baseline before the start of the treatment and at 
the end of every week for a period of 6 weeks during treatment 
using Visual Analog Scale (VAS) for pain. It was scored from 0 to 10 
purely based on patient’s response (Score 0: no pain; Score 10: 
severe pain). 
Mouth opening 
Mouth opening was assessed by measuring the interincisal distance 
from the mesioincisal edge of the maxillary right central incisor to 
the mesioincisal edge of the mandibular right central incisor using 
vernier callipers. If either of the teeth were missing, their left side 
counterpart was used for measurement. Moth opening was recorded 
at baseline before the start of the treatment and subsequently at  the  
end of every week for 6 weeks during treatment period. It was also 
recorded post treatment at 3 and 6 month follow-up period. 
Statistical analysis 
Mean and Standard Deviation were estimated for each study group. 
Normality of the data was tested in each group by using Kolmogrove 
Smirnov test. Mean values were compared between different study 
groups by using Kruskal-Wallis One Way ANOVA followed by Mann-
Whitney U-Test after adjusting the p-values for multiple comparison 
by using Bonferroni Correction method. Mean values were 
compared between different time points within the same group by 
using Wilcoxon Signed Rank Sum Test. In the present study, p < 0.05 
was considered as the level of significance. 
RESULTS 
Age and sex distribution 
All the patients fall within the age range of 18 to 49 years with 
maximum number of patients in the age group of 21 to 30 years. 
Eleven patients in group A, nine patients in group B and 7 patients in 
group C were in this age group (Table 1). All the 45 patients were 
male. 
Table 1: Shows Age Distribution of Patients 

















All the patients included under the study had the habit of chewing 
arecanut either in the pure form or in the form of gutkha, pan masala 
or mawa. The most common form of areca nut used was Gutkha 
(64.4%). 29 out of 45 patients were using it. The median duration of 
habits was 5 yrs (range: 1 to 15years). The median frequency of 
chews per day was 5 times (range: 1 to 20 times).   
Burning sensation 
The mean VAS scores at baseline before start of treatment among 
patients in group A, B and C were 7.5, 7 and 7.5 respectively. All the 
patients in Group A, B and C reported complete relief of burning 
sensation (score 0) within 3 weeks of the start of treatment. 
Mouth opening 
Change in mouth opening among Group A 
The average increase in mouth opening from baseline (before 
treatment) to week 6 was 4.9 ± 2.5 mm. When the average mouth 
opening values from week 1 to 6 were compared with the baseline 
value, the results were found to be statistically significant (‘p’ value: 
< 0.0001, 0.001, 0.001, 0.001, 0.001 and 0.001 respectively). (Fig.1) 
A bar chart demonstrating average change in mouth opening during 
treatment period in Group A. 
 
Figure 1: It Shows Changes in Mouth Opening in Group A 
Change in mouth opening among Group B 
The average increase in mouth opening from baseline (before 
treatment) to week 6 was 4.3 ± 0.8 mm. The results were statistically 
significant when the average mouth opening values from week 1 to 6  
 
were compared with the baseline value (‘p’ value: < 0.0001, < 
0.0001, 0.001, 0.001, < 0.0001 and 0.001 respectively). (Fig.2) 
A bar chart demonstrating average change in mouth opening during 
treatment period in Group B. 
 
Figure 2: It Shows Changes in Mouth Opening in Group B 
Change in mouth opening among Group C 
The average increase in mouth opening from baseline (before 
treatment) to week 6 was 3.4 ± 0.5 mm. When the average mouth 
opening values from week 1 to 6 were compared with the baseline 
value, the results were found to be statistically significant (‘p’ value: 
< 0.0001, < 0.0001,  < 0.0001,  < 0.0001,  < 0.0001 and < 0.0001 
respectively). (Fig.3) 
A bar chart demonstrating average change in mouth opening during 
treatment period in Group C. 
 
Figure 3: It Shows Changes in Mouth Opening in Group C 
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Intergroup comparison in mouth opening 
When the average mouth opening values between baseline and week 
6 was compared among all the three groups (A, B and C), there was 
statistically significant change between Group A and Group C, and 
Group B and Group C (‘p’ value: < 0.0001). (see table 2, Fig.4) There 
was no change in the mouth opening at 3 and 6 months. 
TABLE 2: SHOWS INTERGROUP COMPARISON IN MOUTH OPENING BETWEEN BASELINE AND WEEK 6 
Time points compared Group Mean ± S.D. Overall            p-value Significant Groups 
Week 0 to Week 6 A 4.9  ± 2.5 <0.0001 (Sig.) A vs. C 
B vs. C 
 
B 4.3  ± 0.8 
C 3.4  ± 0.5 
 
A bar chart demonstrating average change in mouth opening from 
baseline to week 6 among Group A, B and C. 
 
Figure 4: It Shows Intergroup Comparison in Mouth Opening 
Adverse effects 
No adverse effects were reported during the treatment period as 
well as during follow-up. 
DISCUSSION 
Oral submucous fibrosis is well known for its chronic and resistant 
nature. The conservative drug treatment that is currently available 
for OSF is clearly inadequate. No single drug has provided complete 
relief of symptoms of OSF 2; this has lead to the use of combination 
of drugs to treat the condition. 
Lycopene is a major carotenoid found in tomato which has potent 
anticancer activity in many types of cancer 6. The antioxidant 
properties of lycopene are thought to be primarily involved in its 
preventive effects in chronic diseases. It also has potent benefits in 
oral potentially malignant lesions like leukoplakia 4. Because of its 
high number of conjugated dienes, lycopene is one of the most 
potent antioxidants, with a singlet-oxygen-quenching ability twice as 
high as that of β-carotene and 10 times higher than that of α-
tocopherol 7. The antioxidant potential has been ranked as follows: 
lycopene > α-tocopherol > α-carotene > ß-cryptoxanthin > 
zeaxanthin = ß-carotene > lutein [8]. OSF is well known for its high 
rate of malignant transformation which is about 2.3 to 7.6% 2. In 
this regard, the antioxidant properties of lycopene may be of great 
benefit by withholding its progression to carcinoma. 
In our study, all the patients were males (100%). It clearly 
demonstrates male predominance of the condition. This was in 
accordance with the study conducted by Ranganathan et al which 
recorded a male to female ratio of 9.9:1 among OSF patients [9]. 
Maximum number of patients (27 out of 45 patients; 60%) in our 
study fell under the age group of 21 to 30 years which was similar to 
the findings of Maher et al who reported that 70% of males with OSF 
were below 30 years of age [10]. When considering the habit of 
chewing arecanut, most of the patients in our study chewed Gutkha 
(64.4%). OSF was more prevalent among Gutkha chewers than the 
other forms of arecanut. The study conducted by Bathi et al was also 
in agreement with this fact [11].   
In OSF grades I and II, the mouth opening of the patients are not 
affected. The efficacy of lycopene and other antioxidants is similar in 
early stages of OSF when mouth opening is normal 2. But the  
 
difference arises only when restriction in mouth opening sets in. 
Also Kumar et al suggests that severe cases of OSF are poor 
responders to lycopene 3. So in our study, we included patients only 
with grade III and IV OSF.  The improvement in mouth opening from 
baseline (before start of treatment) to week 6 was statistically 
significant among all the three study groups A, B and C.  
When intergroup comparisons were made with regard to mouth 
opening, there was significant difference between Group A (lycopene 
with intralesional steroids) and C (intralesional steroids alone) as 
well as Group B (antioxidants with intralesional steroids) and C 
(intralesional steroids alone) (‘p’ value < 0.0001). But even though 
Group A (lycopene with intralesional steroids) showed greater 
improvement in mouth opening (34.9 ± 5.6) than Group B 
(antioxidants with intralesional steroids) (32.2 ± 6.7), the results of 
Group A and B did not differ enough to be statistically significant (‘p’ 
> 0.05).  
This clearly indicates that lycopene is more efficacious than other 
antioxidants when used in combination with intralesional steroids to 
treat OSF. The improvement in mouth opening observed in our 
study can be attributed to two reasons: 1. Lycopene exerts its anti-
inflammatory action by increasing the lymphocyte resistance to 
stress [12],  inhibition of pivotal pro-inflammatory mediators, such 
as the reduction of reactive oxygen species, the inhibition of 
synthesis and release of pro-inflammatory cytokines, changes in the 
expression of cyclooxygenase and lipoxygenase, modifications of 
eicosanoid synthesis, and modulation of signal transduction 
pathways, including that of the inducible nitric oxide synthase [13]. 
2. Lycopene has been shown to inhibit hepatic fibrogenesis in LET 
rats by Kitade et al [14]. A similar action may be expected in OSF. 
We believe that lycopene when combined with intralesional steroids 
offer more benefit than when used alone. Our view is also supported 
by Chole et al 2. But it was contradicting with the findings of Kumar 
et al who stated that the results were better when lycopene is used 
alone 3. In our study, the greater improvement in mouth opening 
when lycopene was combined with intralesional steroids may be 
attributed to the synergistic effect obtained when both the drugs 
were used together. 
 Our study clearly demonstrates that Lycopene in combination with 
intralesional steroids and Hyaluronidase, is highly efficacious in 
improving the mouth opening and reducing other symptoms in 
patients with Oral Submucous Fibrosis. No side effects were 
reported with its usage; hence it proves to be a completely safe drug 
when compared with the other treatment options available for oral 
submucous fibrosis. It can be prescribed either alone as a first-line 
drug in early stages of the disease or in combination with 
intralesional steroids in moderate stages of OSF. Further studies 
with larger sample size should be undertaken to substantiate its 
efficacy in the management of oral submucous fibrosis and to 
demonstrate the probable mechanisms through which it exerts its 
action. 
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